Research at Oslo University Hospital


Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.


Latest news

Oslo Cancer Cluster Innovation Park officially opened

Norum (left) and Einarsson during the opening ceremony (photo Anders Beyer)
Norum (left) and Einarsson during the opening ceremony (photo Anders Beyer)

Early 2000, Jónas Einarsson, CEO at the Radium Hospital Research Foundation, and Kaare Norum, former principal of the University of Oslo, realized that a natural cluster for cancer research, development and innovation emerged in the Oslo-area. Together they established Oslo Cancer Cluster, a research and industry cluster within cancer.

Oslo Cancer Cluster Innovation Park AS was officially opened August 24th 2015 by the Prime Minister of Norway, Erna Solberg.


New English version of "The Research Handbook- from idea to publication" is available


An new English version of "The Research Handbook- from idea to publication" is available on Oslo University Hospital website as of August 27 2015.
The website presents both a Norwegian and English updated version of the Handbook, including simple "Downhill Ski Tracks" for Researchers, PhD students and their projects.

The Research Handbook is designed to provide guidance to hospital personnel,health researchers and biomedical researchers who would like to convert an idea into a high quality research project.


Chronicle on personalised cancer medicine in Aftenposten

Illustration photo: Aftenposten
Illustration photo: Aftenposten

Norway's largest newspaper Aftenposten recently printed a chronicle on personalized cancer medicine, entitled "Should every cancer patient become their own research project"? Here, leader of the National Cancer Genomics Consortium, professor Ola Myklebost, and colleagues professors Per Eystein Lønning, Bjørn Tore Gjertsen and Ragnhild A. Lothe point out that in "personalized medicine", cancer patients remain the largest and increasing group that may benefit most from new treatment strategies.
The authors emphasize the importance of increase in national clinical trials and participation in high quality international studies for the benefit of the Norwegian cancer patient and to strengthen the Norwegian professional development and research.


Training course August 25:

Preparing for the upcoming health calls for Horizon 2020


New calls for EUs Work Programme 2016–2017 - "Health, demographic change and wellbeing" - will be published in September/October 2015. The first deadlines for proposal submissions are most likely in Q1 2016. The call text has a wide scope but also clear priorities. It is a challenge to interpret the text and decode how individual ideas and research can match the text.
A training course will be held by The external funding team at the Dept for Research Administration & Biobank at OUS on Tuesday August 25th.
The Norwegian Research has published an article containing useful advices for the application process, based on experiences from SINTEF during the first round of Horizon 2020 calls.


Novel method reveals new knowledge about G1-phase

First author Tine Weise Håland
First author Tine Weise Håland

A recent collaborative study from the Department of Radiation Biology (Håland, Boye, Stokke, Grallert, Syljuåsen) describes a novel method to simultaneously measure minichromosome maintenance proteins (MCMs) loading and passage through the RB1-dependent restriction point in single cells.
The results are recently (August 6th) published in Nucleic Acids Research (journal impact factor 9.1).


H.M. the King's Gold Medal to Sigrid Bratlie Thoresen

S.B. Thoresen
S.B. Thoresen

Sigrid Bratlie Thoresen in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Biomedicine has been awarded His Majesty the King's Gold Medal 2015 for the best PhD thesis at the Faculty of Medicine

The Medal will be awarded at a Prize Ceremony at the Annual Celebration of the University of Oslo on 2nd September.